Keregen is a UK-based spin-out from the School of Pharmacy, University College London. Keregen Therapeutics is an early stage drug discovery company founded in late 2015, after winning the global bio-entrepreneurship competition, OneStart. The company is focused on the development of first generation small molecule therapies that slow or stop the progression of complex degenerative diseases for which there is unmet clinical need. The principle R&D program, which is in the early lead optimization stage, is to advance proprietary selective Nrf2 activators for the treatment of Parkinson’s disease.
1 job with Keregen
An excellent opportunity for a Graduate Chemist to join Keregen: Winner of the world’s largest Biotech Start-up Accelerator!